Sacituzumab Govitecan-hziy: A Novel Antibody-Drug Conjugate for the Treatment of Triple-Negative Breast Cancer

Sacituzumab Govitecan-hziy is authorized to treat the following conditions:

  • Adults who have had at least two systemic treatments, including at least one for metastatic disease, are candidates for this treatment.
  • Urothelial cancer (a kind of cancer that develops in the lining of the bladder or urinary system) that has spread or is resistant to surgery. Individuals who’ve had platinum-based chemotherapy and immunotherapy get this. The FDA’s Accelerated Approval Program has authorized this usage.

Confirmatory trials must prove sacituzumab govitecan-hziy offers a therapeutic benefit in these patients as a condition of approval.

Sacituzumab govitecan-hziy is also under research for use in the treatment of other cancers.

Detailed scientific definition- Definition from the NCI Drug Dictionary

Sacituzumab Govitecan-hziy – MedlinePlus Information A summary of key facts regarding this medication in layman’s terms, which may contain the following:

Cautions about this medicine.

What it’s in use for and how to use it.

Things you should tell your doctor before taking it.

What you should know about it before using it.

Other drugs that might interact with it.

And possible negative effects

Drugs are frequently under investigation to see whether they can assist treat or prevent conditions. This excludes those for which they have authorization. Only authorized uses of the medication come under this patient information leaflet. Much of the material, though, might also apply to authorized uses that are under investigation.